LINC01001 Promotes Progression of Crizotinib-Resistant NSCLC by Modulating IGF2BP2/MYC Axis

LINC01001 Promotes Progression of Crizotinib-Resistant NSCLC by Modulating IGF2BP2/MYC Axis

Background: Crizotinib is a microtubule-related protein-4-anaplastic lymphoma kinase (EML4-ALK) multi-target tyrosine kinase inhibitor applied in the treatment of ALK-rearranged NSCLC. However, the specific molecular mechanism underlying its therapeutic effect remains unclear. Therefore, the purpose...

Full description

Bibliographic Details
Main Authors:	Meiling Zhang, Qian Wang, Zihao Ke, Yijing Liu, Huijin Guo, Shencun Fang, Kaihua Lu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-09-01
Series:	Frontiers in Pharmacology
Subjects:	crizotinib-resistance NSCLC crizotinib IGF2BP2 LINC01001 MYC
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2021.759267/full

Similar Items

lincROR influences the stemness and crizotinib resistance in EML–ALK+ non-small-cell lung cancer cells
by: Yang Y, et al.
Published: (2018-06-01)

Clinical Efficacy of Crizotinib in Treatment of Patients with Advanced NSCLC
by: Emei GAO, et al.
Published: (2016-03-01)

Crizotinib Resistance Mediated by Autophagy Is Higher in the Stem-Like Cell Subset in ALK-Positive Anaplastic Large Cell Lymphoma, and This Effect Is MYC-Dependent
by: Chuquan Shang, et al.
Published: (2021-01-01)

Front‐line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression control
by: Shih‐Hao Huang, et al.
Published: (2019-12-01)

Tissue distribution of crizotinib and gemcitabine combination in a patient-derived orthotopic mouse model of pancreatic cancer
by: Richard J. Honeywell, et al.
Published: (2016-12-01)

The role of brigatinib in crizotinib-resistant non-small cell lung cancer
by: Mezquita L, et al.
Published: (2018-01-01)

Incidence of ROS1-Rearranged Non-Small-Cell Lung Carcinoma in India and Efficacy of Crizotinib in Lung Adenocarcinoma Patients
by: Mehta A, et al.
Published: (2020-02-01)

Effect of the patient information brochure in communicating the risks associated with crizotinib treatment to patients with non‐small cell lung cancer (NSCLC) in Europe
by: Kui Huang, et al.
Published: (2020-04-01)

Clinical Efficacy of Crizotinib in Advanced ALK Positive  Non-small Cell Lung Cancer
by: Jing ZHAO, et al.
Published: (2015-10-01)

Crizotinib and Sunitinib Induce Hepatotoxicity and Mitochondrial Apoptosis in L02 Cells via ROS and Nrf2 Signaling Pathway
by: Lin Guo, et al.
Published: (2021-02-01)

Real World Experience of Crizotinib in 104 Patients With ALK Rearrangement Non-small-cell Lung Cancer in a Single Chinese Cancer Center
by: Chang Liu, et al.
Published: (2019-10-01)

Efficacy and Safety of Crizotinib in Advanced or Recurrent  ALK-positive Non-small Cell Lung Cancer
by: Xiaoyan LI, et al.
Published: (2019-08-01)

Identification of a novel ALK variant intrinsically resistant to crizotinib
by: Ullas Batra, et al.
Published: (2020-12-01)

Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
by: Wenxian Wang, et al.
Published: (2019-02-01)

A Case of Lung Adenocarcinoma Harboring a Rare LOC285000-ALK-NCK2 Gene Fusion Identified by Next-Generation Sequencing With Long-Term Response to Crizotinib
by: Min Zhang, MBBS, et al.
Published: (2021-02-01)

Use of crizotinib for refractory ALK-positive lymphomas
by: L N Shelikhova, et al.
Published: (2017-07-01)

NCOA1–ALK: a novel ALK rearrangement in one lung adenocarcinoma patient responding to crizotinib treatment
by: Cao Q, et al.
Published: (2019-02-01)

Crizotinib in treatment of lung cancer
by: Arpita Singh, et al.
Published: (2017-01-01)

Successful Crizotinib Rechallenge after Crizotinib-Induced Organizing Pneumonia in Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer
by: Nobuhiro Asai, et al.
Published: (2014-09-01)

Crizotinib-induced osteitis mimicking bone metastasis in a stage IV ALK-rearranged NSCLC patient: a case report
by: F. Guisier, et al.
Published: (2020-01-01)

The potential role of HGF-MET signaling and autophagy in the war of Alectinib versus Crizotinib against ALK-positive NSCLC
by: Xing Huang
Published: (2018-02-01)

Cost-Effectiveness Analysis Of Ceritinib And Alectinib Versus Crizotinib In The Treatment Of Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer
by: Liu M, et al.
Published: (2019-10-01)

ROS1 rearrangement and response to crizotinib in Stage IV non-small cell lung cancer
by: Moushumi Suryavanshi, et al.
Published: (2017-01-01)

Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies
by: Alberto D’Angelo, et al.
Published: (2020-11-01)

Mutations in EMT-Related Genes in ALK Positive Crizotinib Resistant Non-Small Cell Lung Cancers
by: Jiacong Wei, et al.
Published: (2018-01-01)

Clinical Research of Crizotinib in Advanced Non-small Cell Lung Cancer
by: Haibo ZHU, et al.
Published: (2013-06-01)

Real-World Use and Outcomes of ALK-Positive Crizotinib-Treated Metastatic NSCLC in US Community Oncology Practices: A Retrospective Observational Study
by: Craig Reynolds, et al.
Published: (2018-05-01)

Reactive Oxygen Species (ROS)-Sensitive Prodrugs of the Tyrosine Kinase Inhibitor Crizotinib
by: Bjoern Bielec, et al.
Published: (2020-03-01)

Early‐onset interstitial pneumonitis in a patient with advanced non‐small cell lung cancer treated with crizotinib and osimertinib
by: Yuan Cheng, et al.
Published: (2021-03-01)

Interaction of Crizotinib (as an anti lung cancer drug) on Pure, Boron-Doped, and Carboxylated C60 Fullerene: Based on Density Functional Theory
by: Ashrafsadat Ghasemi, et al.
Published: (2020-10-01)

Cost Saving Opportunities in NSCLC Therapy by Optimized Diagnostics
by: Ilija Nenadić, et al.
Published: (2017-07-01)

Good Tolerance to Full-Dose Crizotinib in a Patient with Anaplastic Lymphoma Receptor Tyrosine Kinase-Rearranged Lung Adenocarcinoma and Preexisting Renal Impairment
by: Adeline Rosoux, et al.
Published: (2017-05-01)

A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies
by: Piha-Paul SA, et al.
Published: (2021-05-01)

Treatment of Patients with ALK Gene Rearranged Non-small Cell Lung Cancer  after Resistance to Crizotinib
by: Tao JIANG, et al.
Published: (2015-02-01)

Intestinal metastasis from primary ROS1-positive lung adenocarcinoma cancer patients responding to crizotinib
by: Chen HF, et al.
Published: (2018-11-01)

A retrospective study of alectinib versus ceritinib in patients with advanced non–small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed
by: Chih-Hsi Scott Kuo, et al.
Published: (2021-03-01)

Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK‐positive non‐small cell lung cancer: A retrospective, real‐world study
by: Guangjian Yang, et al.
Published: (2019-10-01)

Crizotinib, a MET inhibitor, inhibits growth, migration, and invasion of breast cancer cells in vitro and synergizes with chemotherapeutic agents
by: Ayoub NM, et al.
Published: (2017-10-01)

The effects of crizotinib in a transgenic Drosophila model expressing the human TPM4-ALK fusion gene or TPM4
by: Yoo Jin Kim, et al.
Published: (2019-07-01)

Focus on Alectinib and Competitor Compounds for Second Line Therapy in ALK Rearranged NSCLC
by: Samuel J Klempner, et al.
Published: (2016-11-01)

Cannot write session to /tmp/vufind_sessions/sess_300n8g64hh3o78o0amm7s8jt6e